Xgeva (denosumab), which has already been approved by the Food and Drug Administration (FDA) for the prevention fractures in men with advanced prostate cancer that has already migrated to the bone, has been rejected by the FDA to expand the use of the drug to delay the spread of tumors in men without metastases to [...]
Despite the fact that we have had good research for well over 15 years that show that early hormone therapy increases over all survival, some doctors still insist on delaying the start of hormone therapy. A UK randomized trial done in 1997 demonstrated a slight impact of immediate versus deferred hormone suppression in advanced prostate [...]
For those who might be interested in the April 23, 2012 edition of The New Yorker Magazine, Jerome Groopman has written an excellent article on the history and current state of Immunotherapy. The article is entitled "The T-Cell Army" and it is on page 24. Not only does the article review the history (going all [...]
I am interrupting the reviews of the AACR meeting to inform you of a very important piece of news. Men with advanced prostate cancer which is castrate resistant and who have 2 blaistic bone metastases may now have access to Alpharadin even though the FDA has not yet approved it in the United States! It [...]
Patient Power, a Partner Organization of Malecare, just released a Skype interview they made with me about some aspects of the recent AACR meeting in Chicago. I talk about the exciting results from the Phase II trial of Prostvac, a small phase II study of Pomegranate juice for men with prostate cancer as well as [...]